U.S. Diversified Products’ revenue trends
In 1H17, Valeant Pharmaceuticals International’s (VRX) U.S. Diversified Products franchise reported revenues of $519.0 million compared to $848.0 million in 1H17. In 2Q17, it generated revenues of $255.0 million, which reflects a ~27.0% rise on a YoY (year-over-year) basis.
In 2Q17, Solta and Obagi generated revenues of $9.0 million and $16.0 million, respectively, compared to $6.0 million and $14.0 million, respectively, in 2Q16. In 2Q17, Solta and Obagi rose 50.0% and 14.0%, respectively, on a YoY basis.
In 2Q17, Valeant Pharmaceuticals’ neurology and generics generated revenues of $248.0 million and $82.0 million, respectively, compared to $344.0 million and $122.0 million, respectively, in 2Q16.
Revenue trends of top US diversified products
In 1H17, Wellbutrin, Isuprel, Xenazine, Syprine, and Cuprimine reported revenues of $107.0 million, $71.0 million, $61.0 million, $47.0 million, and $40.0 million, respectively. That compares to $147.0 million, $106.0 million, $89.0 million, $43.0 million, and $52.0 million, respectively, in 1H16.
In 2Q17, Wellbutrin, Isuprel, Xenazine, Syprine, and Cuprimine generated revenues of $28.0 million, $33.0 million, $32.0 million, $27.0 million, and $20.0 million, respectively. That reflects falls of 28.0%, 18.0%, 24.0%, and 35.0%, respectively, YoY. In 2Q17, Wellbutrin, Xenazine, and Syprine rose 18.0%, 10.0%, and 35.0%, respectively, on a QoQ (quarter-over-quarter) basis.
In 2Q17, Ativan, Migranal, Mephyton, and Aplenzin generated revenues of $16.0 million, $15.0 million, $9.0 million, and $9.0 million, respectively. That reflects a 78.0% rise, a 6.0% fall, a 36.0% fall, and an 18.0% fall, respectively, YoY.
The PowerShares Dynamic Pharmaceuticals ETF (PJP) invests ~2.1% of its total portfolio holdings in Valeant Pharmaceuticals.